Government
Biogen to expand rare disease treatment efforts with $7B-plus acquisition
The Alzheimer’s treatment developer which has a significant presence in Research Triangle Park says it will pay $172.50 in cash for each share of Texas-based…
Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.
The Alzheimer’s treatment developer which has a significant presence in Research Triangle Park said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year.
Plano, Texas-based Reata focuses on developing treatments that regulate cellular metabolism and deal with inflammation in serious neurologic diseases. It makes Skyclarys, an FDA-approved treatment for the neurologic disorder Freidreich’s ataxia.
Biogen puts an enterprise value of $7.3 billion on the acquisition, and said it would slightly dilute adjusted earnings per share this year, and be roughly neutral next year before becoming “significantly accretive” in 2025.
Regulators and Reata shareholders still need to approve the deal.
Biogen makes the multiple sclerosis treatments Techfidera and Tysabri as well as the spinal muscular atrophy treatment Spinraza. It also is partnering with Japanese drugmaker Eisai to sell the new Alzheimer’s treatment Leqembi.
CEO Christopher Viehbacher said in a statement the company’s experience developing and selling rare disease treatments will help expand the market for Skyclarys, which is being reviewed by European regulators.
Friedreich’s ataxia is caused by a gene defect inherited from both parents, according to Johns Hopkins Medicine. It can lead to vision and hearing loss and trouble walking, among other symptoms.
Shares of Reata Pharmaceuticals Inc. jumped 13% to $123 in pre-market trading Friday. Biogen Inc.’s stock slipped 1%.
The post Biogen to expand rare disease treatment efforts with $7B-plus acquisition first appeared on WRAL TechWire.
Here Are the Champions! Our Top Performing Stories in 2023
It has been quite a year – not just for the psychedelic industry, but also for humanity as a whole. Volatile might not be the most elegant word for it,…
AI can already diagnose depression better than a doctor and tell you which treatment is best
Artificial intelligence (AI) shows great promise in revolutionizing the diagnosis and treatment of depression, offering more accurate diagnoses and predicting…
Scientists use organoid model to identify potential new pancreatic cancer treatment
A drug screening system that models cancers using lab-grown tissues called organoids has helped uncover a promising target for future pancreatic cancer…
